South Africa’s Competition Commission has referred pharmaceutical manufacturer Adcock Ingram’s hospital division to the Competition Tribunal for prosecution over alleged excessive pricing of kidney dialysis products. The referral, announced on 3 June 2026, targets Adcock Ingram Critical Care (AICC) and covers pricing for peritoneal dialysis and continuous renal replacement therapy (CRRT) products between July 2019 and June 2024. The commission…
Tag: Natco Pharma
-
Adcock Ingram Delisting After Natco Acquisition
Pharmaceutical giant Adcock Ingram has confirmed its delisting from the Johannesburg Stock Exchange (JSE) on 11 November 2025. The move marks the end of its 17-year run as a public company. This follows the finalisation of a R4.2 billion acquisition scheme by the Indian-based Natco Pharma. The company announced that it had fulfilled or waived all conditions precedent for the…
-
Adcock Ingram Takeover Gets Green Light from Shareholders
Shareholders in Adcock Ingram, the renowned South African pharmaceutical company, have decisively approved a takeover offer from Indian drugmaker Natco Pharma. This paves the way for the company to delist from the Johannesburg Stock Exchange (JSE) after 16 years. At a general meeting last week, shareholders voted 98.66% of shares in favour of the offer. The deal will see Natco…
-
Adcock Ingram Reports Flat Profit Despite Winter Surge
Pharmaceutical giant Adcock Ingram has announced flat annual profits despite a significant recovery in the second half of its financial year. This was buoyed by strong demand for its popular over-the-counter winter medicines. In a landmark move, the maker of household staples like Panado and Corenza-C is also set to delist from the Johannesburg Stock Exchange (JSE). This follows a…
-
Bidvest’s Role in Adcock Ingram Takeover Bid
In a striking case of corporate déjà vu, South African pharmaceutical firm Adcock Ingram is once again the subject of a foreign takeover bid. However, the script has been flipped. Bidvest, the conglomerate that positioned itself as the company’s patriotic saviour over a decade ago, is now orchestrating its sale to an overseas partner. This culminates in a patient power…
-
Adcock Ingram to Delist Amidst Corporate Changes
Adcock Ingram, the pharmaceutical giant behind household brands such as Panado and Corenza-C, could delist from the Johannesburg Stock Exchange (JSE). This follows a significant deal between its majority shareholder, Bidvest, and Indian drugmaker Natco Pharma. The news saw Adcock’s share price surge by 24%. Under the terms of the agreement, Indian-listed Natco Pharma will acquire a significant minority stake…